Effect of carnitine supplementation in treatment of women with polycystic ovary syndrome

Clinical trial of the effect of carnitine supplementation compared with the placebo on carotid intima-media thickness and biomarkers of inflammation in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017070433941N3

Enrollment

Registered

2017-07-31

Start date

2016-07-11

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 250 mg carnitine (Avecina, Tehran, Iran), once a day, for 12 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), once a day, for 12

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with polycystic ovary syndrome according to Rotterdam criteria Aged 18 to 40 years

Exclusion criteria

Exclusion criteria: Pregnant women Elevated levels of prolactin Endocrine diseases

Design outcomes

Primary

Measure	Time frame
Mean left CIMT. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.;Maximum left CIMT. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.;Mean right CIMT. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.;Maximum right CIMT. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.	—

Measure

Time frame

Mean left CIMT. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.;Maximum left CIMT. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.;Mean right CIMT. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.;Maximum right CIMT. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.

—

Secondary

Measure	Time frame
Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 36 1534 3570

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026